



## CYNATA THERAPEUTICS LIMITED (PREVIOUSLY ECO QUEST LIMITED)

### REINSTATEMENT TO OFFICIAL QUOTATION

The securities of Cynata Therapeutics Limited (the "Company") were suspended from Official Quotation on Monday, 28 October 2013.

The securities of the Company will be reinstated to Official Quotation from the commencement of trading on Friday, 29 November 2013, following the Company's compliance with listing rule 11.1.3 and chapters 1 and 2 of the ASX Listing Rules.

<u>Quoted Securities:</u>	44,906,701 fully paid ordinary shares
	11,164,701 Options exercisable at \$0.20 each on or before 31 December 2014
<u>ASX Code:</u>	CYP, CYPO
<u>Time:</u>	10.00am EDST (7.00am WST)
<u>Date:</u>	29 November 2013
<u>ASX Trade Abbreviation:</u>	CYNATA THR
<u>ISIN:</u>	AU000000CYP7 AU000000CYPO3
<u>Home Branch:</u>	Perth
<u>Industry Classification:</u>	Pharmaceuticals, Biotechnology & Life Sciences
<u>Registered Office:</u>	Suite 1, 1233 High Street Armadale VIC 3143
<u>Principal Place of Business:</u>	8 High Street South Kew VIC 3101
	Tel: +61 3 9824 5254 Fax: +61 3 9822 7735
<u>Company Secretary:</u>	Mr Peter Webbe

#### ASX Circular

**Date** 29 November 2013

#### Key topics

1. Cynata Therapeutics Limited
2. ASX Code: CYP, CYPO
3. Reinstatement

#### Reading List

Client Advisers  
Corporate Advisory  
DTR Operators  
Institutions  
Listing Officers  
ASX Settlement Participants  
Office Managers  
Operations Managers (back office)  
Research Analysts  
Share Registries  
ASX Clear Participants  
Market Participants

#### Authorised by

Adam Russo

#### Contact

Adam Russo

#### Telephone

(08) 9224 0000

ASX Limited  
ABN 98 008 624 691  
Exchange Centre  
20 Bridge Street  
Sydney NSW 2000  
PO Box H224  
Australia Square NSW 1215

Internet: <http://www.asx.com.au>

No responsibility is accepted for any inaccuracies contained in the matter published.

For personal use only

<u>Share Registry:</u>	Security Transfer Registrars Pty Ltd 770 Canning Highway Applecross WA 6153  Tel: +61 8 9315 2333 Fax: +61 8 9315 2233
<u>Balance Date:</u>	30 June
<u>CHESS:</u>	Participating. The Company will also operate an issuer sponsored sub-register
<u>State of Incorporation:</u>	Western Australia
<u>Dividend Policy:</u>	See page 77 of the Company's prospectus
<u>Activities:</u>	Stem cell and regenerative medicine development
<u>Restricted Securities</u>	10,000,001 fully paid ordinary shares, classified by ASX as restricted securities to be held in escrow for a period of 12 months commencing from their date of issue being 22 November 2013.  5,000,000 unquoted options exercisable at \$0.40 each on or before 27 September 2018, classified by ASX as restricted securities to be held in escrow for a period of 24 months commencing from the date the Company's securities are reinstated to official quotation.  500,000 unquoted options exercisable at \$0.40 each on or before 9 September 2016, classified by ASX as restricted securities to be held in escrow for a period of 24 months commencing from the date the Company's securities are reinstated to official quotation.
<u>Unquoted Securities</u>	25,000 unquoted options exercisable at \$3.98 cents each on or before 30 November 2013

For further information please refer to the Company's prospectus dated 14 October 2013